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Background/aim: NLRP3 inflammasome activation has been known to be involved in the etiology and progression of Alzheimer’s
disease (AD). Furthermore, AD and diabetes mellitus have common pathomechanisms. It has been shown that P2X7R whose
expression is increased in brain tissues with AD and plays a role in the activation of NLRP3 inflammasome is suppressed by miR-373
in patients with osteoarthritis. Therefore, the question of whether the suppressive effect of miR-373 on NLRP3 may have a role in the
pathophysiology of AD comes to mind. On the other hand, it is known that the miR-204 level increases in response to TXNIP, another
NLRP3 inflammasome inducer with high expression in AD. In primary human islets, miR-204 reduces the expression of GLP-1R. It has
been discovered that in vivo deletion of miR-204 is protective against diabetes by increasing GLP-1R and insulin secretion. Considering
the relationship between miR-204 and TXNIP and the relationship of miR-204 with diabetes suggests investigating the effect of miR-204
on the inflammatory pathway in AD. Based on the common pathophysiological mechanisms between AD and diabetes and the reported
changes related to NLRP3 inflammasome, we analyzed miR-373 and miR-204 in neuron-derived serum exosomes in this study. Neuronderived exosomes in neurodegenerative diseases are considered to be better candidates for developing potential biomarkers.
Materials and methods: The expression levels of miR-204 and miR-373 were investigated in neuron-derived serum exosomes obtained
from 15 patients with mild AD, 18 with moderate AD, and 21 cognitively healthy individuals.
Results and discussion: The miR-204 and miR-373 expressions were significantly decreased in both patient groups compared to the
control group. Therefore, we suggest that miR-204 and miR-373 are potential biomarkers for AD. However, due to the preliminary
nature of this study, further large-scale studies are needed to support our findings.
Key words: MiR-204, miR-373, Alzheimer’s disease, neuron derived exosomes, NLRP3 inflammasome, TXNIP, P2X7R, GLP-1R

1. Introduction
The most common cause of age-related dementia worldwide
is Alzheimer’s disease (AD), a neurodegenerative disorder
[1]. Globally, one in 10 people over 65 live with AD, and
its prevalence is expected to almost triple by 2050 [2,3].
Late-onset AD accounts for the majority of cases with the
disease (>90%–95%). In its etiology, multiple genetic risk
factors, as well as environmental factors are implicated. To
date, mutations with low penetrance have been reported
[4]. Although the best-known susceptibility gene is APOE
[5] , a large number of new genetic loci have been identified
in genome-wide association studies associated with the
risk of developing AD [6]. These include loci associated
with immune response (CLU, ABCA7, and CR1) and

lipid metabolism (SORL1, PICALM, and CD2AP) [7–12].
In recent years, with the widespread use of sequencing
techniques, rare variants with lower frequency have been
identified in some genes associated with AD; e.g., TREM2
[12], PLD3 [13], and UNC5C [14].
In vivo and in vitro studies show that amyloid β
peptide and Tau protein are the main elements that form
the pathogenesis of AD. Neurobiological mechanisms,
such as amyloid hypothesis, cholinergic hypothesis, Tau
phosphorylation, oxidative stress, and calcium homeostasis
are considered in the etiopathogenesis of AD [15]. There
is also evidence in the literature that neuroinflammatory
changes are involved in the etiology and progression of the
disease [16].
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miRNAs
have
important
effects
on
the
posttranscriptional regulation of gene expression, and
although they do not encode proteins, they have become
the focus of attention due to their potential as biomarkers
in the diagnosis, monitoring and treatment of various
diseases. miRNA expression changes observed in many
diseases, including AD have been associated with the
pathogenesis of the disease [17].
Exosomes are extracellular vesicles that play important
roles in the signal transduction and transport of molecules.
The evaluation of content carried by exosomes has brought
up their potential to be used in the monitoring of diseases.
It is anticipated that they may provide a great advantage in
neurodegenerative diseases, such as AD, which requires a
definitive diagnosis and invasive procedures [18,19].
Recently, the activation of NLR family pyrin domaincontaining 3 (NLRP3) inflammasome with amyloid β (Aβ)
has been shown to play a critical role in the pathogenesis
of AD and provide the basis for IL-1β maturation and
subsequent inflammatory events [20]. The expression
of P2X purinoceptor 7 (P2X7R) around the amyloid
plaque has been shown to increase in APP (amyloid
precursor protein) mutant transgenic mice having high
APP expression. After the in vivo inhibition of P2X7R,
the number of hippocampal amyloid plaques decreased
significantly in mouse models [21]. Zhang et al. showed
that miR-373 suppressed the P2X7R expression by binding
to the 3’UTR of P2X7R in patients with osteoarthritis and
reduced inflammation and chondrocyte proliferation in
these patients via suppressing the inflammatory factors
such as IL-6 and IL-8 [22]. On the other hand, Sorensen et
al., who obtained the miRNA profile from the cerebrospinal
fluids of patients with AD found no significant change in
miR-373 expression levels compared to the control group
[23]. However, the expression of miR-373 in neuronderived exosomes from serum has not been analyzed until
now. In the current study, considering effect of miR-373
on P2X7R, the expression level of miR-373 in the neuronderived exosomes of patients with AD was examined.
Previous studies have shown that the binding of
thioredoxin-interacting protein (TXNIP) to NLRP3 is
significant for inflammasome activation and insulin
resistance [24]. In many neurodegenerative diseases,
including AD, the level of TXNIP expression has
been shown to increase [25,26]. Amelioration in Tau
phosphorylation has been observed as a result of the
inhibition of TXNIP and NLRP3 inflammasome [27]. Jo
et al. described TXNIP as the upstream regulator of miR204. In response to TXNIP, the miR-204 level increased.
miR-204 was found to be lower in beta cell-specific TXNIP
knockout mice [28]. On the other hand, the presence of
Type 2 diabetes mellitus (DM) increases the risk of AD
[29]. The mechanism underlying this relationship is

deficiencies in insulin and glucagon-like peptide 1 (GLP1) signal. GLP-1, which is expressed from the soma and
dendrites of large neurons, shows a neuroprotective effect
against the toxic activities of Aβ1-42. It is known that the
cells of the hippocampus and the hypothalamus highly
express glucagon-like peptide 1 receptor (GLP-1R) [30,
31]. Jo et al. showed that miR-204 suppressed GLP-1R
expression in primary mouse and human pancreatic islets
by targeting the 3’UTR of GLP-1R [28]. In a study by
Solensen et al., there was no significant change in miR-204
expression in the cerebrospinal fluids of patients with AD
compared to the control group [23]. Nevertheless, based
on the above-mentioned studies, we investigated miR-204
expression in the neuron-derived exosomes of patients
with AD in the current study.
According to the literature, there are many studies
related to miRNAs in neurodegenerative diseases,
including AD. It is known that the expression changes
in the detected miRNAs contribute to the pathogenesis
of AD from different aspects. In a study, low miR-153
levels were found to contribute to Aβ accumulation in
individuals with sporadic AD [32]. Aβ plaques result from
an imbalance between the production and degradation
of amyloid peptides. Increased levels of miR-128 impair
Aβ clearance by targeting lysosomal enzymes in sporadic
Alzheimer’s patients [33]. In another study, it has been
observed that the increase of miR-188-5p in primary
hippocampal neurons reduces synaptic and cognitive losses
[34]. miR-138, whose increased expression is observed in
Alzheimer’s patients, has also been shown to induce Tau
hyperphosphorylation by suppressing GSK-3β (glycogen
synthase kinase-3b) activity [35]. Furthermore, miR-137
has been shown to reduce Aβ-induced neurotoxicity via
suppressing the NF-kB pathway[36].
In recent studies, the diagnostic yield of inflammatory
miRNAs in AD has been investigated. For instance,
Souza et al. detected the downregulation of miR-9-5p
in whole blood samples of AD patients compared to the
control group [37]. In another study, it has been shown
that the plasma levels of miR-17-5p, miR-21-5p, and
miR-126-3p in a cohort of AD patients were upregulated
compared to healthy controls [38]. Here, we focused on
the pathomechanism of NLRP3 inflammasome and the
common mechanisms of AD with diabetes. As noted above,
we chose miR-373 and miR-204 as a preliminary study,
based on the knowledge of previous studies that mentioned
the expression change of P2X7R and TXNIP shown in AD
and the regulatory effect of miR-373 and miR-204 on them.
We planned to conduct a study on the exosomes of neural
origin considering that it would provide more accurate
information related to the pathogenesis of AD different
from the above-mentioned studies in methodological
terms. In addition, it was thought that the use of exosomes
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obtained from peripheral blood could become a routine
procedure in the diagnosis and follow-up of this patient
group. Furthermore, exosomes have therapeutic potential
since miRNAs can be modified according to the detected
expression changes and sent to the target.
2. Materials and methods
2.1 Participants
This study was approved by the ethics committee of
the university and all procedures were undertaken in
accordance with the latest version of the Declaration
of Helsinki. Informed consent was obtained from all
participants after a detailed explanation of the experimental
procedure. The competencies of the volunteers in the
patient group were evaluated by a neurologist and a
psychiatrist. For those who were found to be incompetent,
the consent was obtained from the legal representatives of
the patients.
Fifteen patients with mild AD (Mi-AD), 18 with
moderate AD (Mo-AD) and 21 older healthy volunteers
were included in the study. The patients were evaluated
at the geriatric psychiatry and neurology departments of
a university hospital. Patients who were diagnosed with
probable AD according to the diagnostic criteria of the
National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association [39] and who were compatible with
the mild and moderate stages according to the Clinical
Dementia Score (CDS) [40] were included in the study.
None of the patients had any family history related to AD,
and all were aged ≥60 years.
All the patients underwent MRI scans which were
routinely performed for clinical diagnoses. The Scheltens’
scale for medial temporal atrophy was used to evaluate the
level of medial temporal atrophy (hippocampal atrophyHA) as a biomarker in the patients [41]. In addition,
since the patients’ vascular brain lesions would make the
interpretation of the findings difficult, especially due to
eliminating possible accompanying vascular dementia,
only those who scored 0 (no white matter lesion) or 1 (one
or two white matter lesions with no tendency to merge)
in the Fazekas scale were included in the sample [42]. The
Turkish version of the Mini-Mental State Examination
was administered to both the control and AD groups [43].
The detailed information of all the participants is given as
supplemental data.
The exclusion criteria of the study were having another
neurological disease that could impair cognitive evaluation
(ischemic or hemorrhagic cerebrovascular disease, mental
retardation, epilepsy, Parkinson’s disease, non-Alzheimer’s
type of dementia, motor neuron disease, alcohol and
substance dependence, etc.), advanced stage AD (CDS =
3), DM, and Fazekas scale score > 1.
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The control group was selected from cognitively
healthy volunteers. The exclusion criteria for this group
were having a neurological disease that could impair
cognitive assessment and the presence of a DM diagnosis.
2.2 Collection of samples from participants
Twenty mL of peripheral blood was collected from each
participant with a sterile syringe and then transferred to
serum separator tubes. It was allowed to clot for 30–45 min
at room temperature. After coagulation, it was centrifuged
at 500 g for 10 min. Then, 5 mL serum was taken from
the supernatant portion with a Pasteur pipette. The serums
were stored in aliquots at −80 °C until use [44].
2.3 Isolation of total exosomes and L1CAM-positive
neuron-derived exosomes
The serum sample was thawed at 4 °C. Two-hundred µL of
the precipitation buffer A solution (miRCURY Exosome
Serum/Plasma Kit, Qiagen, catalog no: 76603) was added
to 0.5 mL serum and vortexed for 5 s. The mixture was
incubated at 2–8 °C for 60 min. Then, it was centrifuged at
1500 g for 30 min at 20 °C. The remaining supernatant was
discarded. Two hundred and seventy µL of resuspension
buffer was added to the tube containing the pellet and
resuspended by vortexing. A final volume of ~300 µL was
obtained.
Two µg (4 µL) of mouse antihuman CD171 (L1CAM,
neural adhesion protein) biotinized antibody (Thermo
Fisher) and 100 µL 3% blocker BSA were added to 250 µL
suspension of exosomes obtained by exosome isolation
[45]. The sample was incubated in a rotator mixer for
60 min at 4 °C. After incubation, 15 µL Streptavidin
UltraLink Resin (Thermo Fisher) and 40 µL 3% blocker
BSA were added. Following incubation for 30 min at 20
°C, the sample was centrifuged at 3000 g for 10 min at 4
°C. The supernatant was discarded. To remove neuronal
exosomes trapped in resin, 200 µL of 0.1M glycine-HCl
(pH:3) was added to the pellet and mixed for 30 s with a
quick vortex. It was centrifuged at 4500 g for 10 min at 4 °C,
and then the supernatant was removed, and neutralization
was achieved by adding 15 µL of 1M TRIS-HCl (pH:8).
Phosphate-buffered saline was added until the suspension
reached a volume of 300 µL.
2.4 miRNA isolation from L1CAM-Positive neuronal
exosomes
miRNA was extracted using spin column chromatography
(miRNeasy Serum/Plasma Kit, Qiagen catalog no:
217184). Five mL of QIAzol Lysis Reagent was added to
300 µL of sample and mixed by vortexing. Twenty µL of
the carrier RNA solution was added, and the sample was
incubated for 5 min at room temperature. One mL of
chloroform was added, and the tube was tightly capped
and vortexed vigorously. After incubation for 2–3 min
at room temperature, it was centrifuged at 1500 g for 15
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min. The upper aqueous phase was transferred to a new
collection tube. Then, 100% ethanol was added at 1.5 times
of the volume of the sample. It was mixed thoroughly by
pipetting. Seven hundred µL of the sample was added
into the RNeasy MinElute spin column, which was then
centrifuged at ≥8000 g for 15 s at room temperature. This
step was repeated until the sample was finished. Seven
hundredµL of the buffer RWT was added to the RNeasy
MinElute spin column, capped, and centrifuged at 8000 g
for 25 s. The bottom part was discarded. Five hundred µL
of the buffer RPE was added to the RNeasy MinElute spin
column, capped, and centrifuged at 8000 g for 25 s, and
the bottom part was discarded. Five hundred µL of 80%
ethanol was added to the RNeasy MinElute spin column.
The lid was closed and centrifuged at ≥8000 g for 2 min
15 s. The bottom and collecting tubes were discarded.
The RNeasy MinElute spin column was placed in a new
2 mL collection tube. The spin column was opened and
centrifuged at full speed for 5 min to dry the membrane.
The bottom and collecting tubes were discarded. The
RNeasy MinElute spin column was placed in a new 1.5
mL collection tube. Fourteen µL of RNase-free water was
directly placed in the center of the spin column membrane.
It was slowly capped and centrifuged for 1 min 15 s at full
speed to obtain miRNA.
2.5 cDNA synthesis and real-time PCR
cDNA synthesis was performed with the miRCURY
LNA Reverse Transcription (RT) Kit, Qiagen (catalog no:
339340) from the obtained miRNAs. To obtain cDNA, each
miRNA sample was incubated for 60 min at 42 °C in the
presence of 5 × miRCURY RT Reaction Buffer, RNase-free
water, 10x miRCURY RT Enzyme Mix (for miR-204-5p,
miR-373-3p, U6 snRNA (for endogenous control). RT was
inactivated within 5 min at 95 °C, and the cDNA samples
were cooled at 4 °C. cDNA samples for real-time PCR were
mixed with 2x miRCURY SYBR Green Master Mix, PCR
primer mix, and RNase-free water (mirCURY LNA RT
Kit, Qiagen catalog no:339340). The plates were run on the
QIAGEN’s real-time PCR cycler, Rotor-Gene Q.
2.6 Evaluation of results and statistical analysis
Reactions for both the target miRNA (miR-204 and
miR-373) and endogenous control (U6 snRNA) were

performed against a negative template control in each
case and control. U6 snRNA was used as a reference for
normalization. The miR-204, miR-373 and U6 snRNA
cycle threshold (Ct) values of each case and control were
determined by averaging the Ct values emerging from
their two reactions. The Ct values for U6 snRNA, miR-204,
and miR-373 of the patient and control groups are given
as supplemental data. Using the obtained data, miRNA
expression changes were calculated with the 2−ΔΔCt (Livak)
method as previously described [46].
Data obtained from the study were summarized
using descriptive statistics. For this purpose, the mean
± standard deviation [median (minimum-maximum)]
values were calculated for the miR-204 and miR-373
levels. The compatibility of the measurements obtained
from the groups to the normal distribution was examined
with the Kolmogorov-Smirnov test, and the homogeneity
assumption of the group variances was examined with the
Levene test. Since the data showed a normal distribution,
the significance of the difference between the groups was
examined with a one-way analysis of variance (ANOVA),
and the group from which the difference originated was
examined with the Dunnet test. p < 0.05 was considered
statistically significant.
3. Results
A sample consisting of 15 patients with mild AD, 18 with
moderate AD, and 21 healthy controls was investigated.
The participants’ demographic and clinical information
are given in Table 1. The Ct1, Ct2, and average Ct values of
each participant are given in supplemental data. The mean
Ct values for U6 snRNA, miR-204, and miR-373 are shown
in Table 2, and the average delta Ct values which were
calculated using the mean Ct values are presented in Table 3.
The fold change of gene expressions shows the results
found with the 2 −ΔΔCt (Livak) method. As shown in Table
4a, the expression levels were observed as 0.14-fold for
hsa-miR-204 in the mild AD group and 0.04-fold in the
moderate AD group compared to the control group. For
hsa-miR-373, the fold change was 0.27 in the mild AD
group and 0.16 in the moderate AD group compared to the
control group. In Figure, the fold change values of the mild

Table 1. Sociodemographic and clinical characteristics of the participants. Mi-AD: Mild Alzheimer’s disease group, Mo-AD: Moderate
Alzheimer’s disease group, HC: Healthy control group, M: Male, F: Female, MMSE: Mini-Mental State Examination, SD: Standard
deviation
n

Gender (M: F)

Mean age ± SD

Mean years of education ± SD

Mean MMSE score ± SD

Mi-AD

15

6:9

71.40 ± 7.76

8.27 ± 5.42

23.7 ± 2.8

Mo-AD

18

4:14

76.94 ± 9.10

6.89 ± 5.42

18.3 ± 4.63

HC

21

12:9

66.38 ± 6.07

Not documented

28.3 ± 1.32
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and moderate AD groups for miR-204 and miR-373 are
shown graphically compared to the control group. After U6
snRNA normalization, the “fold change” values calculated
for both miRNAs in the mild and moderate AD groups
were found to be decreased compared to the control group.
p values were determined by applying Student’s t-test
to the 2 −ΔΔCt values of each miRNA in the AD and control
groups (Table 4b). For both miRNAs, the expressions were
reduced in the moderate AD group compared to the mild
AD group. While the decrease in the miR-204 expression

in the mild and moderate AD groups was statistically
significant compared to the control group (p = 0.000659
and 0.000051, respectively), the difference between
the mild and moderate AD groups was not statistically
significant (p = 0.131). Similarly, the decrease in the miR373 expression in mild and moderate AD groups was
statistically significant compared to the control group (p
= 0.0224 and 0.00325, respectively), but the difference
between the mild and moderate AD groups was not
statistically significant (p = 0.546).

Figure: Graphical representation of the fold change values of the mild and moderate stage AD groups for miR204 and miR-373 compared to the control group.

Table 2. Average Ct values for U6 snRNA, miR-204, and miR-373. Ct: Cycle threshold, Mi-AD: Mild Alzheimer’s disease group, Mo-AD:
Moderate Alzheimer’s disease group, HC: Healthy control group.
Mean Ct values

Standard deviation

P value

HC

Mi-AD

Mo-AD

HC

Mi-AD

Mo-AD

U6 snRNA

20.84

24.74

21.49

1.542940

1.554326

1.634782

<0.001

hsa-miR-204

21.52

28.30

26.90

2.238471

2.336613

2.036743

<0.001

hsa-miR-373

24.85

30.65

28.13

1.118668

1.896381

2.386306

<0.001

Table 3: Average delta Ct values for U6 snRNA, miR-204, and miR-373. Mi-AD: Mild Alzheimer’s disease group, Mo-AD: Moderate
Alzheimer’s disease group, HC: Healthy control group, Ct: Cycle threshold.
Mean delta (Ct) [Ct (AD group)–Ct
(HC)]

Standard deviation

HC

Mi-AD

Mo-AD

HC

Mi-AD

Mo-AD

U6 snRNA

0.00

0.00

0.00

0.000000

0.000000

0.000000

hsa-miR-204

0.68

3.56

5.40

1.959049

2.018526

1.867945

hsa-miR-373

4.01

5.91

6.64

1.504755

1.043574

1.289807
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Table 4a. Fold change (2’ Ct) values for miR-204 and miR-373 compared to the control group. Mi-AD: Mild
Alzheimer’s disease, Mo-AD: Moderate Alzheimer’s disease, Ct: Cycle threshold.
Fold change (2−ΔΔCt) (compared to the control group)
Mi-AD group

Mo-AD group

U6 snRNA

1.00

1.00

hsa-miR-204

0.14

0.04

hsa-miR-373

0.27

0.16

Table 4b. p values of the miR-204 and miR-373 expression levels in AD groups compared to the control group. AD:
Alzheimer’s disease, Mi-AD: Mild Alzheimer’s disease group, Mo-AD: Moderate Alzheimer’s disease group.
p-values (compared to the control group)
Mi-AD

Mo-AD

U6 snRNA

N/A

N/A

hsa-miR-204

0.000659

0.000051

hsa-miR-373

0.0224

0.00325

4. Discussion
Studies carried out to date, have shown that exosomes in the
central nervous system (CNS) carrying mRNA, noncoding
RNA, and DNA are involved in many important processes
such as intercellular communication, trophic support of
neurons, antigen presentation, and synaptic plasticity [47].
Since it is considered that exosomes reflect the inside of the
cell better than other body fluids in terms of their nucleic
acid and protein contents, they have recently been the focus
of interest in studies aiming to reveal the pathogenesis of
neurodegenerative diseases. In addition, it has been shown
that exosomes are more advantageous than cell-free RNAs
due to the amount of RNA content [48]. There are some
biomarker studies using neuron-derived exosomes that
express CD171 as a surface marker to reflect CNS diseases
more specifically. It has been shown that autolysosome
protein levels in neuron-derived exosomes from the blood
samples of AD cases are higher than in the control group,
which may be a predictor of AD before clinical onset [49].
Furthermore, Walsh et al. found that miR-212 and miR132 levels in neuron-derived exosomes were lower in the
plasma samples of patients with AD than in the control
group [50]. In another miRNA profile study comparing
the total plasma extracellular vesicles population and
neuron-derived extracellular vesicles, it was observed that
the levels of miR-23a-3p, miR-223-3p, and miR-190a-5p
increased whereas the miR-100-3p levels decreased [51].
However, the use of plasma as a source of exosomes creates
difficulties due to the coagulation factors found in the
plasma content which may coprecipitate with exosomes.

Therefore, additional procedures are required, such as
the use of EDTA or heparin to reduce coagulation and
obtain pure exosomes [52]. We predicted that the use of
serum instead of plasma would be more advantageous
since it does not require an additional procedure from a
methodological point of view. In addition, although there
are studies concerning the altered expression of miRNAs
in exosomes isolated from plasma in patients with AD as
mentioned above, there is no information in the literature
regarding the expression changes of miRNAs in neuronderived exosomes from the serum samples of this patient
group. For these reasons, in the current study, neuronderived exosomes were extracted using the anti-CD171
(L1CAM) antibody from the serum samples of 15 mild
and 18 moderate AD cases and 21 volunteers without
any cognitive deficit. Then, total miRNAs were obtained
from the neuron-derived exosomes, and the miR-204 and
miR-373 expressions were analyzed in the AD and control
groups. The expression of both miRNAs was found to be
significantly lower in the mild and moderate AD groups
than in the controls. However, the difference between
the mild and moderate AD groups was not statistically
significant for miR-204 or miR-373.
In a study examining the postmortem brain tissues
of a transgenic mouse model of AD, it was shown that
the expression and function of P2X7R were upregulated
[21]. In patients with osteoarthritis, miR-373 has been
shown to suppress P2X7R expression by binding to its
3’UTR and decrease inflammation and chondrocyte
proliferation in these patients [22]. Sorensen et al., who
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obtained the miRNA profile from the cerebrospinal fluids
of patients with AD reported no significant change in
miR-373 expression compared to the control group [23].
To date, no study has associated miR-373 with AD. We
consider that the lower miR-373 levels of our patients
with AD compared to the control group indicate that
P2X7R could not be suppressed in these patients, and
as a consequence the NLRP3 inflammasome pathway
was activated, contributing to neuroinflammation. This
mechanism can be more clearly demonstrated in further
studies investigating the expression of P2X7R in AD and
control groups and comparing the results with the miR373 expression data.
A review of the literature suggests an increase in the
expression of miR-204 in patients with AD compared
to the control group based on publications reporting an
increase in miR-204 in response to TXNIP in diabetic
patients or decreased expression of GLP-1R by miR-204
[28]. However, our results revealed a low level of miR204 expression in both AD groups compared to the
control group. There are very few studies on this subject
in the literature. This finding can be explained by miRNAs
having a large number of unspecified target genes and the
presence of factors that control their expression which
have not yet been fully identified. However, there are
some studies supporting our results. In a study examining
frontotemporal dementia (FTD), a patient group carrying
mutation in one of the three genes (C9orf72, GRN, and
MAPT), presymptomatic individuals carrying mutations,
and a healthy control group that did not carry any mutation
were evaluated, and the expression levels of miR-204 in
exosomes obtained from cerebrospinal fluid were shown
to be lower in the symptomatic patients compared to the
other groups [53]. As a result of the in silico analysis, the
authors reported that HRK, which encodes the apoptosis
activator HARAKIRI, was one of the target genes of miR204 [53,54]. Considering the common neurodegeneration
mechanisms in FTD and AD, the lower miR-204 levels
in our AD group may have upregulated HRK and caused
apoptosis and neurodegeneration. In another study, the

expression levels of miR-204 in the hippocampus of APP/
PS1 mutant transgenic Alzheimer’s mouse models were
found to be low. After the administration of lentivirus
infusion over-expressing miR-204 to the same mice,
it was shown that the amyloid plaque burden of mice
was reduced, and memory loss was improved [55]. The
compatibility of our results with the studies mentioned
above shows the effectiveness of the use of neuron-derived
exosomes as biomarkers for the early diagnosis, follow-up
and treatment of neurodegenerative diseases.
In our study, although the miR-204 and miR-373
expression levels were found to be lower in the moderate
AD group compared to the mild AD group,

this finding
can be interpreted as progressing neurodegeneration in
these patients. However, in order to support this inference,
it is necessary to conduct a study with a larger sample size.
Although the use of neuron-derived exosomes is predicted
to provide increased specificity in understanding the
pathophysiology of CNS diseases, such as AD, this requires
a comparison of data obtained from studies examining the
miRNA expression levels of total exosomes isolated from
serum samples.
It would be ideal to carry out a transcriptome analysis
and analyze the expression profile of miRNAs in patients
with AD of different stages and in healthy volunteers from
different age groups, but this would increase the cost
tremendously. Therefore, the current study was designed
as preliminary research. In future studies, it is planned to
expand the sample size and conduct extensive research to
determine the target genes of these miRNAs.
There is not yet a specific treatment for AD. Today,
studies on biomarkers that can be detected in the early
stages of the disease have gained importance. Instead of
biomarkers, such as total Tau, phosphorylated Tau-181,
and Amyloid β proteins in the cerebrospinal fluid [56,
57], which are obtained by invasive protocols, the plasma
phosphorylated Tau-217 is a promising alternative [58, 59].
Similar studies seeking plasma or serum biomarkers can
offer new horizons for both the early diagnosis and potential
therapeutic targets for AD with increasing prevalence.
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